6.92 USD
▼-1.16-14.36%
盘后 6.88 -0.58%
2026-09-15
市值
$140.42M
市盈率
—
EPS
-6.09
股息率
—
52 周区间
6.33 – 20.56
成交量
3.76M
Beta
2.64
目标价
34.03
52W 低 6.3352W 高 20.56
价格走势
公司简介
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.